PSMB9 and nasopharyngeal carcinoma: In a phase II trial, patients with EBV+ nasopharyngeal carcinomas were first treated with four cycles of chemotherapy followed by up to six does of EBV-specific T cells recognizing viral protein LMP2 (Chia et al., 2014).